BofA raised the firm’s price target on Krystal Biotech (KRYS) to $325 from $318 and keeps a Buy rating on the shares. The firm increased Vyjuvek expectations, removed KB104 and KB105 builds and added a Hailey-Hailey disease build, with its updates resulting in changes to its per share contributions from dermatology programs, respiratory programs, aesthetics, oncology and cash, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech price target raised to $284 from $224 at Guggenheim
- Krystal Biotech price target raised to $323 from $220 at Chardan
- Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline
- Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages
- Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target